Atezolizumab, which targets PD-L1, has been approved as a primary monotherapy for metastatic NSCLC patients with high PD-L1 levels and as an adjuvant treatment for resected stage II-IIIA NSCLC patients (105). Here, CD274 is linked to non-small cell lung carcinoma.